TOP 100 MEDICAL SITES
| |||
|
| |||
| |||
|
| |||
| Pfizer, Washington University Collaborate to Find New Uses for Old Drugs The Burrill Report submits: Pfizer (PFE) is trying to breathe new life into old drugs through what it is describing as a first-of-a-kind collaboration between academia and industry. The pharmaceutical giant said it has agreed to give scientists at Washington University School of Medicine in St. Louis access to information regarding more than 500 pharmaceuticals and pharmaceutical candidates as part of a partnership that seeks to find new uses for existing compounds. Under the five-year agreement, Pfizer will provide $22.5 million to Washington University and give its scientists access to research data on a large array of Pfizer pharmaceutical candidates that are currently or were formerly in clinical testing. The agreement is unusual because it calls for Pfizer to share proprietary data on its compounds with the university researchers, something pharmaceutical companies do not typically do. Complete Story » seekingalpha.com |
Experts Urge Earlier AIDS Treatment Despite its notorious reputation, the virus that causes AIDS doesn't infect the human body easily, and the difficulties HIV has point to potential new prevention and treatment methods, according to a growing body of research. online.wsj.com |
BioClinica Partners with Axio Research Corporation and Beardsworth Consulting Group (Business Wire) NEWTOWN, Pa.----BioClinicaâ„¢, Inc., , a global provider of clinical trial management services, today announced it has created strategic partnerships with two privately held clinical research organizations , Axio Research Corporation and Beardsworth Consulting Group, Inc. us.rd.yahoo.com |
Sanofi's Hostile Bid: Despite Problems, Genzyme Has Value Sanofi-Aventis (NYSE: SNY) said Monday that it has launched an $18.5 billion hostile offer for biotech company Genzyme (Nasdaq: GENZ), after it became fed-up with the Genzyme board's "unwillingness to engage" in discussions. The $69 per share offer is unchanged from the friendly proposal Sanofi-Aventis made privately to Genzyme's board of directors in July, which was promptly rejected publicly in August.Complete Story » seekingalpha.com |
Tengion Announces First Implantation of Neo-Urinary Conduit in Initial Clinical Trial in Patients with Bladder Cancer [PR Newswire] - Tengion, Inc. , a leader in regenerative medicine, announced today that surgeons at the University of Chicago have implanted its Neo-Urinary Conduitâ„¢ in the first patient as part of the ongoing clinical trial evaluating the Company's lead product candidate in bladder cancer patients requiring a urinary diversion following bladder removal. us.rd.yahoo.com |